About trifluridine + tipiracil
Antineoplastic combination
Used for
- Metastatic colorectal cancer previously treated with standard therapies
- Metastatic gastric or gastroesophageal junction cancer after prior treatments
Usual adult dose
35 mg/m² trifluridine twice daily, with tipiracil, on days 1–5 and 8–12 of each 28-day cycle; maximum 80 mg trifluridine per dose.
Common side effects
- Low blood-cell counts, including neutropenia and anemia
- Nausea, vomiting, diarrhea, or reduced appetite
- Fatigue
- Fever or infection
Important warnings
- Can cause severe bone-marrow suppression; blood counts require monitoring.
- Serious infections may occur, especially with low white-cell counts.
- May harm an unborn baby; pregnancy testing and contraception are advised.
- Dose changes may be needed for kidney or liver problems.
Pregnancy
May cause fetal harm. Avoid during pregnancy; effective contraception is advised during treatment and for six months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for one day after the last dose.
Interactions
- Medicines affecting BCRP transport, such as cyclosporine, may increase exposure.
- Medicines affecting OCT2 or MATE1 transport, such as cimetidine, may increase exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.